Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, Davis
About this trial
This study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \[18F\]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.
Eligibility criteria
Qualifiers
Men and women age >18 yrs
Biopsy proven NSCLC with brain metastases (treated or untreated)
Life-expectancy of ≥3 months in the opinion of the treating physician
Available archival tumor tissue (excisional, core, or fine needle aspiration (FNA) is acceptable). Tissue from a metastatic site is preferred when available.
Disqualifiers
Pregnant or lactating women
Prisoners
Concurrent malignancy of a different histology that could confound imaging interpretation
Patients who cannot undergo PET/CT scanning because of weight limits(>350lbs)
Trial design
Treatments tested in this trial
- [18F]-αvβ6-BP
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
University of California, Davis
Lead sponsor
United States Department of Defense
Collaborator
Source ClinicalTrials.gov